Liaoning Tumour Hospital

Shenyang, China

Liaoning Tumour Hospital

Shenyang, China
SEARCH FILTERS
Time filter
Source Type

Liu M.-H.,Shenyang University | Wang M.-C.,Shenyang University | Gao N.,Liaoning Tumour Hospital | Li Y.,Shenyang University | Jiang W.-G.,Shenyang University
Chinese Journal of Cancer Research | Year: 2010

Objective: To investigate the expression of glucose regulated proteins GRP78 and GRP94 in human colon cancer. Methods: Tissues of resected primary colon cancer, colon adenoma and normal tissue were investigated. Protein expression was detected with immunohistochemical staining. mRNA expression levels of GRP78 and GRP94 were determined by semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) after mRNA extraction. Results: The expression of GRP94 and GRP78 was significantly higher in colon cancer when compared to those in colon adenoma and normal tissue (P<0.01). GRP94 mRNA and protein expression was found to be in close relationship with the grade of differentiation, Dukes stages, lymph node involvement and remote metastasis in colon cancer (P<0.01), but no relationship with gender and age (P>0.05). GRP78 mRNA and protein expression increased with cancer progression along the normal tissue-adenoma-cancer sequence, but showed no association with grade of differentiation, Dukes stages, lymph node involvement, remote metastasis, gender and age (P>0.05). The mRNA expression of GRP78 and GRP94 was consistent with the proteins (P<0.01), but there is no correlation between overexpression of GRP78 and GRP94 (P>0.05), and the patients with both strong GRP78 and GRP94 protein expression did not show advanced tumor stages (P>0.05). Conclusion: Overexpression of GRP78 and GRP94 was found in colon cancer. Overexpression of GRP94 was closely related to cellular differentiation, Dukes stages, invasion and metastasis. © 2010 Chinese Anti-Cancer Association and Springer Berlin Heidelberg.


Wen F.-Y.,Liaoning Tumour Hospital | Ma T.,Liaoning Tumour Hospital | Yu H.,Liaoning Tumour Hospital
Journal of Dalian Medical University | Year: 2012

[Objective] To evaluate the effectiveness and the cosmetic result of radiotherapy after breast conserving surgery for early breast cancer. [Methods] A total of 97 early invasive breast carcinoma in women who had undergone previous breast-conserving surgery were treated with postoperative irradiation. [Results] The median follow-up time was 60 months, the overall survival rate was 97.3% and the locoregional recurrence rate was 3.21%, as calculated using the Kaplan-Meier method. Excellent and good cosmetic result was noted in 91 patients. [Conclusion] Breast-conserving therapy, consisting of breast-conserving surgery followed by breast radiotherapy, has therefore become the standard regimen for treatment of early invasive breast cancer.


Meng Q.,Liaoning Tumour Hospital | Zhang J.,Liaoning Tumour Hospital | Lian B.,Liaoning Tumour Hospital | Song C.,Liaoning Tumour Hospital
Tumor Biology | Year: 2014

Numerous studies have investigated the risk of colorectal cancer (CRC) associated with the polymorphism of DNA methyltransferase 3B (DNMT3B) 149 C>T, but results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of the association between this polymorphism and risk of CRC. A comprehensive search was conducted to identify all case-control studies of the -149C>T polymorphism of DNMT3B and CRC risk. A total of seven eligible studies, including 2,666 cases and 4,022 controls, relating the DNMT3B polymorphism of -149C>T to the risk of CRC were identified. It suggested no significant associations between -149C>T polymorphism of DNMT3B gene and the risk of developing CRC in the recessive, dominant, and co-dominant models (for CC versus TT: OR = 0.90, 95 % CI = 0.90-1.25, P heterogeneity = 0.37; for recessive model: OR = 0.54, 95 % CI = 0.28-1.04, P heterogeneity = 0.00001; for dominant model: OR = 1.07, 95% CI = 0.93-1.23, P heterogeneity = 0.83; and for C allele versus T allele: OR = 0.70, 95 % CI = 0.43-1.13, P heterogeneity = 0.00001). In the subgroup analysis, there is no significant associations were also found in European populations (for CC versus TT: OR = 1.09, 95 % CI = 0.92-1.30, P heterogeneity = 0.88; for recessive model: OR = 1.00, 95 % CI = 0.88-1.13, P heterogeneity = 0.14; for dominant model: OR = 1.50, 95 % CI = 0.89-2.54, P heterogeneity = 0.00001; and for C allele versus T allele: OR = 0.70, 95 % CI = 0.38-1.28, P heterogeneity = 0.00001). In conclusion, no significant association was found between the -149C>T polymorphisms in DNMT3B and CRC susceptibility. © 2013 International Society of Oncology and BioMarkers (ISOBM).


PubMed | Liaoning Tumour Hospital
Type: Journal Article | Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine | Year: 2014

Numerous studies have investigated the risk of colorectal cancer (CRC) associated with the polymorphism of DNA methyltransferase 3B (DNMT3B) 149 C>T, but results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of the association between this polymorphism and risk of CRC. A comprehensive search was conducted to identify all case-control studies of the -149C>T polymorphism of DNMT3B and CRC risk. A total of seven eligible studies, including 2,666 cases and 4,022 controls, relating the DNMT3B polymorphism of -149C>T to the risk of CRC were identified. It suggested no significant associations between -149C>T polymorphism of DNMT3B gene and the risk of developing CRC in the recessive, dominant, and co-dominant models (for CC versus TT: OR=0.90, 95% CI=0.90-1.25, P heterogeneity=0.37; for recessive model: OR=0.54, 95% CI=0.28-1.04, P heterogeneity=0.00001; for dominant model: OR=1.07, 95% CI=0.93-1.23, P heterogeneity=0.83; and for C allele versus T allele: OR=0.70, 95% CI=0.43-1.13, P heterogeneity=0.00001). In the subgroup analysis, there is no significant associations were also found in European populations (for CC versus TT: OR=1.09, 95% CI=0.92-1.30, P heterogeneity=0.88; for recessive model: OR=1.00, 95% CI=0.88-1.13, P heterogeneity=0.14; for dominant model: OR=1.50, 95% CI=0.89-2.54, P heterogeneity=0.00001; and for C allele versus T allele: OR=0.70, 95% CI=0.38-1.28, P heterogeneity=0.00001). In conclusion, no significant association was found between the -149C>T polymorphisms in DNMT3B and CRC susceptibility.

Loading Liaoning Tumour Hospital collaborators
Loading Liaoning Tumour Hospital collaborators